Does Rallies show Form 4 insider transactions for ATYR?

Yes. Rallies tracks ATYR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ATYR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ATYR. It does not provide personalized investment advice.

ATYR (aTyr Pharma, Inc. Common Stock) Stock Analysis - Insider Trades

aTyr Pharma, Inc. Common Stock (ATYR) is a publicly traded Healthcare sector company. As of May 21, 2026, ATYR trades at $0.54 with a market cap of $50.94M and a P/E ratio of -0.67. ATYR moved +10.04% today. Year to date, ATYR is -28.87%; over the trailing twelve months it is -84.80%. Its 52-week range spans $0.40 to $7.29. Analyst consensus is neutral with an average price target of $7.33. Rallies surfaces ATYR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ATYR stock inside the company?

Recent ATYR insider activity includes Shukla Sanjay sold 3.75K, Broadfoot Jill Marie sold 1.56K, DENYES NANCY sold 1.12K, SCHIMMEL PAUL bought 318.00K, and SCHIMMEL PAUL bought 682.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ATYR Key Metrics

Key financial metrics for ATYR
Metric	Value
Price	$0.54
Market Cap	$50.94M
P/E Ratio	-0.67
EPS	$-0.80
Dividend Yield	0.00%
52-Week High	$7.29
52-Week Low	$0.40
Volume	10.84K
Avg Volume	0
Revenue (TTM)	$190.00K
Net Income	$-74.12M
Gross Margin	0.00%

Recent ATYR Insider Trades

Shukla Sanjay sold 3.75K (~$3.66K) on Feb 4, 2026.
Broadfoot Jill Marie sold 1.56K (~$1.52K) on Feb 4, 2026.
DENYES NANCY sold 1.12K (~$1.09K) on Feb 4, 2026.
SCHIMMEL PAUL bought 318.00K (~$299.36K) on Oct 9, 2025.
SCHIMMEL PAUL bought 682.00K (~$612.44K) on Oct 8, 2025.

Latest ATYR News

Atyr Pharma reports $10.8M Q1 loss, eyes June Phase 3 IND — May 15, 2026
aTyr Pharma Plans June IND Submission for 372-Patient Phase 3 Efzofitimod Trial — May 11, 2026
Atyr Pharma Beats Q4 Loss Estimates, Schedules FDA Meeting on Phase 3 Efzofitimod — Mar 5, 2026

ATYR Analyst Consensus

5 analysts cover ATYR: 0 strong buy, 1 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $7.33.

Common questions about ATYR

Who is trading ATYR stock inside the company?: Recent ATYR insider activity includes Shukla Sanjay sold 3.75K, Broadfoot Jill Marie sold 1.56K, DENYES NANCY sold 1.12K, SCHIMMEL PAUL bought 318.00K, and SCHIMMEL PAUL bought 682.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ATYR?: Yes. Rallies tracks ATYR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ATYR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ATYR. It does not provide personalized investment advice.